$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio.